R3 Vascular

Executive Summary

R3 Vascular is a private medical device company headquartered in Santa Clara, California, focused on developing bioresorbable scaffolds for the treatment of peripheral arterial disease (PAD). Founded in 2018, the company's core technology is an ultra-thin polymer scaffold coated with sirolimus, designed to restore blood flow in diseased arteries and then fully resorb over time, eliminating the need for permanent implants. This approach addresses key limitations of current treatments, such as metal stents that can cause chronic inflammation or restenosis, and drug-coated balloons that lack mechanical support. R3 Vascular's scaffold aims to combine the benefits of acute vessel support with long-term vessel healing and restoration of native vascular function. The technology has the potential to significantly improve outcomes for the growing PAD patient population, which is underserved by existing devices. The company is still in the development stage, with no commercial products or disclosed funding rounds to date. However, the bioresorbable scaffold market is an area of high interest in interventional cardiology and vascular surgery, driven by the demand for ‘leave-nothing-behind’ solutions. R3 Vascular likely faces a path that includes preclinical studies, first-in-human trials, and eventual FDA approvals. Key risks include achieving adequate mechanical strength and optimal degradation kinetics, as well as navigating the regulatory landscape. As a private company, visibility into its progress is limited, but if its technology proves safe and effective, R3 Vascular could become a notable player in the peripheral vascular device space.

Upcoming Catalysts (preview)

• Q4 2026Completion of First-in-Human Clinical Trial Enrollment60% success
• Q3 2026Announcement of Series A or B Financing Round50% success
• Q1 2027Regulatory Submission for an Investigational Device Exemption (IDE) in the US40% success